Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Drug Therapy for Rheumatoid Arthritis in Adults

Slide: 38 of 45

Comparative Adverse Effects of DMARDs for Patients With Early Rheumatoid Arthritis

Adding prednisone to treatment with one or multiple oral disease-modifying anti-rheumatic drugs (DMARDs) does not increase treatment discontinuation rates (treatment durations spanned 2 months to 5 years). The strength of evidence for this finding is moderate.

Combining oral DMARDs (sulfasalazine and methotrexate) increases withdrawal from treatment due to adverse events. The strength of evidence for this finding is low.